Proteomic Comparison of Malignant Human Germ Cell Tumor Cell Lines.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
02
2019
revised:
10
05
2019
accepted:
25
06
2019
entrez:
1
10
2019
pubmed:
1
10
2019
medline:
11
2
2020
Statut:
epublish
Résumé
Malignant germ cell tumors (GCT) are the most common malignant tumors in young men between 18 and 40 years. The correct identification of histological subtypes, in difficult cases supported by immunohistochemistry, is essential for therapeutic management. Furthermore, biomarkers may help to understand pathophysiological processes in these tumor types. Two GCT cell lines, TCam-2 with seminoma-like characteristics, and NTERA-2, an embryonal carcinoma-like cell line, were compared by a quantitative proteomic approach using high-resolution mass spectrometry (MS) in combination with stable isotope labelling by amino acid in cell culture (SILAC). We were able to identify 4856 proteins and quantify the expression of 3936. 347 were significantly differentially expressed between the two cell lines. For further validation, CD81, CBX-3, PHF6, and ENSA were analyzed by western blot analysis. The results confirmed the MS results. Immunohistochemical analysis on 59 formalin-fixed and paraffin-embedded (FFPE) normal and GCT tissue samples (normal testis, GCNIS, seminomas, and embryonal carcinomas) of these proteins demonstrated the ability to distinguish different GCT subtypes, especially seminomas and embryonal carcinomas. In addition, siRNA-mediated knockdown of these proteins resulted in an antiproliferative effect in TCam-2, NTERA-2, and an additional embryonal carcinoma-like cell line, NCCIT. In summary, this study represents a proteomic resource for the discrimination of malignant germ cell tumor subtypes and the observed antiproliferative effect after knockdown of selected proteins paves the way for the identification of new potential drug targets.
Identifiants
pubmed: 31565104
doi: 10.1155/2019/8298524
pmc: PMC6745167
doi:
Substances chimiques
Proteome
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8298524Informations de copyright
Copyright © 2019 Felix Bremmer et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Cancer Res. 2015 Nov 1;75(21):4517-26
pubmed: 26329536
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Science. 2010 Dec 17;330(6011):1670-3
pubmed: 21164013
EMBO J. 2011 Aug 05;30(17):3620-34
pubmed: 21822214
Virchows Arch. 2014 Mar;464(3):301-13
pubmed: 24487784
Oncotarget. 2015 Oct 20;6(32):33426-37
pubmed: 26451610
Oncogene. 2003 Mar 27;22(12):1880-91
pubmed: 12660824
J Pathol. 2008 May;215(1):21-30
pubmed: 18348160
Oncoimmunology. 2015 Dec 18;5(5):e1120399
pubmed: 27467918
Med Sci Monit. 2018 Aug 17;24:5739-5747
pubmed: 30117494
J Biol Chem. 2014 May 30;289(22):15691-704
pubmed: 24733393
J Pathol. 2007 Sep;213(1):72-81
pubmed: 17590861
Int J Mol Sci. 2018 Jun 14;19(6):null
pubmed: 29903985
Mol Cell Oncol. 2015 Oct 2;2(1):null
pubmed: 26989766
Am J Pathol. 2009 Jan;174(1):309-16
pubmed: 19056850
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
JAMA. 2008 Feb 13;299(6):672-84
pubmed: 18270356
APMIS. 2013 Oct;121(10):976-81
pubmed: 23398382
J Med Genet. 2003 Apr;40(4):e50
pubmed: 12676923
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Cancer. 2005 Nov 15;104(10):2092-8
pubmed: 16206293
PLoS One. 2014 Jun 02;9(6):e98330
pubmed: 24887064
Genes Chromosomes Cancer. 2008 Mar;47(3):185-96
pubmed: 18050305
Cancer. 2005 Nov 15;104(10):2255-65
pubmed: 16228988
Int J Androl. 2011 Aug;34(4 Pt 2):e189-203
pubmed: 21649665
Mol Cell Proteomics. 2002 May;1(5):376-86
pubmed: 12118079
J Biol Chem. 2013 Feb 1;288(5):3174-83
pubmed: 23229552
Ann Oncol. 2008 Mar;19(3):448-53
pubmed: 18006893
Gene. 2018 May 15;654:49-56
pubmed: 29462646
Mol Med Rep. 2019 May;19(5):4205-4212
pubmed: 30942427
Oncotarget. 2017 Mar 21;8(12):19934-19946
pubmed: 28193906
PLoS One. 2014 Jan 03;9(1):e83585
pubmed: 24404135
Science. 2010 Dec 17;330(6011):1673-7
pubmed: 21164014
Nature. 2014 Sep 18;513(7518):382-7
pubmed: 25043054
EMBO Mol Med. 2018 Sep;10(9):
pubmed: 30097507
Lab Invest. 1988 Sep;59(3):328-36
pubmed: 2842544
Histopathology. 2016 Jul;69(1):7-10
pubmed: 26918959
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Acta Med Scand. 1962 Jan;171:13-21
pubmed: 13871358
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
Eur J Immunol. 2011 Jun;41(6):1550-62
pubmed: 21469132
Ann Oncol. 2013 Apr;24(4):878-88
pubmed: 23152360
Epigenetics Chromatin. 2010 Apr 27;3(1):9
pubmed: 20423503
Anal Bioanal Chem. 2007 Oct;389(4):1017-31
pubmed: 17668192